(CercleFinance.com) – Moderna and Merck today announced that Merck has exercised its option to jointly develop and commercialize the personalized cancer vaccine (PCV) mRNA-4157/V940 under the terms of the collaboration agreement and license existing between the two partners.
mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, as an adjuvant therapy for high-risk melanoma patients in a Phase 2 clinical trial led by Moderna.
“We have been collaborating with Merck on PCV since 2016 and together we have made significant progress in promoting mRNA-4157 as an investigational personalized cancer treatment used in combination with KEYTRUDA,” said Stephen Hoge, President of Moderna.
Under the agreement, originally established in 2016 and amended in 2018, Merck will pay Moderna $250 million to exercise its option on personalized cancer vaccines, including mRNA-4157/V940, and collaborate in the development and commercialization.
The payment will be expensed by Merck in the third quarter of 2022. Merck and Moderna will share costs and benefits equally in this global collaboration, they say.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
